Effects of alpha lipoic acid on iron overload, lipid profile and oxidative stress indices in ß-thalassemia major patients: A cross-over randomised controlled clinical trial.

AIMS: ß-Thalassemia major (ß-TM) is associated with iron overload, abnormal lipid levels and oxidative stress. Alpha lipoic acid (ALA) showed anti-oxidant and iron chelating properties, but its effect in ß-TM patients is unclear. We investigated the effects of ALA on iron levels, lipid profile and oxidative stress. METHODS: In this cross-over randomised clinical trial, 26 ß-TM patients were assigned to receive 600 mg/d ALA or placebo (corn starch), for 8 weeks with a 21-days washout period. Serum ferritin, total cholesterol, triglycerides, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), LDL-C/HDL-C, total antioxidant capacity, malondialdehyde (MDA) and MDA/LDL-C were assessed at baseline and the end of each intervention phase. RESULTS: Twenty-two patients completed the study. Serum ferritin (P = .004), MDA (P = .025) and MDA/LDL-C ratio (P =.002) were decreased and HDL-C (P =.035) increased significantly during ALA consumption. In comparison with placebo, ALA decreased the serum ferritin significantly (P = .02). Also, the changes in serum ferritin between ALA and placebo (-123.1 ± 40.0 vs -34.3 ± 21.0, P =.03) was significant in women subgroup. ALA had no significant effects on the other biomarkers. CONCLUSION: The results of this study indicated that supplementation with 600 mg/d ALA may decrease serum ferritin in ß-TM. Further studies are needed to confirm the findings.

Probiotic Yogurt Fortified with Vitamin D Can Improve Glycemic Status in Non-Alcoholic Fatty Liver Disease Patients: a Randomized Clinical Trial.

Non-alcoholic fatty liver disease (NAFLD) is a significant public health problem globally and the most notable chronic liver disease in Asian countries. Various dietary supplements have been assessed as potential methods to alleviate the metabolic damages related to NAFLD, but the results of these works have been equivocal. This study aimed to evaluate the effects of probiotic yogurt fortified with vitamin D (Pro-YFD) on glycemic and anthropometric indices in patients with NAFLD. One hundred and four NAFLD patients of both sexes were randomly allocated to 2 groups: group A (Pro-YFD) and group B (unfortified yogurt). The intervention period was 3 months. Fasting blood samples were obtained for measuring fasting blood sugar (FBS) and insulin level. Food intake was measured using a validated food frequency questionnaire. Body composition was estimated by bio-impedance. Eighty-eight patients completed the study. The mean serum level of 25(OH)D3 was elevated significantly (p < 0.001), while insulin level decreased significantly (p < 0.003) in group A at the end of the study. FBS levels showed no significant differences between the groups at the end of the trial. Also, there were no significant changes in diet caloric intake, physical activity, or anthropometric indices in the 2 groups during the interventions. Pro-YFD in the diets of patients with NAFLD may attenuate insulin resistance and improve serum level of 25(OH)D3.

The effect of green tea on prostate specific antigen (PSA): A systematic review and meta-analysis of randomized controlled trials.

BACKGROUND: Prostate cancer is a major malignancy, affecting men, worldwide. The protective effect of green tea consumption on prostate cancer has been reported in several studies; however, the findings are equivocal. OBJECTIVE: The aim of this study was to evaluate the effects of green tea on PSA level, by conducting a systematic review and meta-analysis of randomized controlled trials. METHODS: We searched online databases, including PubMed, Scopus, and Web of Science, up to 11 Aug 2020, to obtain relevant publications. The publication search was not limited by language or date. RESULTS: A total of 2488 records were identified in the systematic search; from these, seven were included in the meta-analysis. The overall analysis showed no significant changes in PSA levels in subjects treated with green tea, (WMD: ‒0.60 ng/mL; 95 % CI: ‒1.32, 0.12 ng/mL; P = 0.104, I2 = 93.80 %, P heterogeneity<0.001). Subgroup analysis based on geographical location showed that green tea significantly reduced PSA level in the USA population (WMD: ‒1.02 pg/mL, 95 % CI: ‒1.30, ‒0.73, P < 0.001) compared to non-USA populations (WMD: ‒0.22 pg/mL, 95 % CI: ‒0.95, 0.50, P = 0.539) (P < 0.001). CONCLUSION: The results of this review show that green tea has no significant effect on PSA level. However, due to the heterogeneity among studies more consistent clinical trials, with larger sample sizes are required.

Effects of vitamin D supplementation on core symptoms, serum serotonin, and interleukin-6 in children with autism spectrum disorders: A randomized clinical trial.

OBJECTIVES: Children with autism spectrum disorders (ASD) have lower serum vitamin D and higher serotonin and interleukin (IL)-6 levels compared with healthy children. The aim of this study was to evaluate the effect of vitamin D on core symptoms and serum levels of serotonin and IL-6 in these children. METHODS: This parallel randomized double-blind, placebo-controlled trial was conducted with 43 children with ASD (7 girls and 36 boys; 8.91 ± 2.87 y of age). Children were randomly allocated to receive either vitamin D drop (300 IU/kg up to a maximum of 6000 IU daily) or placebo for 15 wk. Serum levels of 25-hydroxyvitamin (OH)D, IL-6, and serotonin were measured at baseline and at the end of the trial. Also, the severity of autism and the social and individual maturity of the children were measured by the Childhood Autism Rating Scale (CARS), the Autism Treatment Assessment Checklist (ATEC), and Aberrant Behavior Checklist-Community (ABC-C) questionnaires before and after intervention. Randomization and allocation to groups were done using computer-generated numbers. RESULTS: More than 86% of patients had vitamin D deficiency at the beginning of the study. Serum levels of 25(OH)D increased significantly in the vitamin D group (P = 0.001). The clinical symptoms of autism measured by CARS and ATEC scales were alleviated significantly (P = 0.021 and P = 0.020, respectively); however, the serum levels of serotonin and IL-6 and the scale of ABC-C remained without a significant change. CONCLUSION: These findings suggest that vitamin D supplementation may improve ASD symptoms; however, more studies with longer duration are indispensable to confirm our results.

Effects of Alpha-Lipoic Acid Supplementation on Cardiovascular Disease Risk Factors in ß-Thalassemia Major Patients: A Clinical Trial Crossover Study.

AIM: Thalassemia is one of the most common genetic diseases, and cardiovascular disease (CVD) has been considered as the leading cause of mortality in more than 50% of ß-thalassemia patients. The aim of this study was to determine the effects of alpha-lipoic acid (ALA) on CVD risk factors in ß-thalassemia major patients. METHODS: Twenty ß-thalassemia major patients participated in this randomized crossover clinical trial study. Participants were randomly assigned to ALA (600 mg/day) or placebo groups for two 8-wk interventions that were separated by a 3-wk washout period. The CVD risk factors including serum osteoprotegerin (OPG), homocysteine, lipoprotein-associated phospholipase A2 and trimethylamine N-oxide were measured at the beginning and the end of each intervention phase according to the standard protocol. RESULTS: Serum OPG reduced significantly in the ALA group in all participants (5.38 ± 2.79 to 3.27 ± 2.43 ng/mL, P= .003) and in the male subgroup (5.24 ± 2.56 to 3.13 ± 2.5 ng/mL, P= .015); this reduction was significant in comparison with the placebo group (P= .013). The changes in other CVD risk factors were not significant. CONCLUSION: The results of this study showed that after 8-wk of ALA consumption, the serum OPG reduced significantly in ß-thalassemia major patients. Therefore, controlling the serum OPG level with ALA consumption can be an important complementary therapeutic option to prevent the progression of CVD in ß-thalassemia major patients.

Antihyperlipidemic and Antioxidative Properties of Pistacia atlantica subsp. kurdica in Streptozotocin-Induced Diabetic Mice.

INTRODUCTION: Pistacia atlantica subsp. kurdica is an important food source and a well-known medicinal plant in the Zagros Mountains of Iran. The present study aimed to investigate the effect of P. atlantica extract and essential oil in streptozotocin-induced diabetic mice. MATERIALS AND METHODS: Different doses of hydroalcoholic extract and essential oil of P. atlantica subsp. kurdica (50, 100, and 200 mg/kg) were given to streptozotocin-induced diabetic mice in separate groups for three weeks. At the end of treatment, blood samples were collected; then, oxidative stress markers, TNF-α, and lipid profile were determined in its serum samples. RESULTS: Our findings showed that the administration of P. atlantica extract for three consecutive weeks significantly improved the lipid profile, oxidative stress, and inflammation process by reducing lipid peroxidation and increasing total antioxidant capacity. CONCLUSION: This study showed that P. atlantica subsp. kurdica has antioxidant and blood lipid-lowering effects that can be used as a supplement to improve diabetes complications.

Effects of Chromium Picolinate Supplementation on Cardiometabolic Biomarkers in Patients with Type 2 Diabetes Mellitus: a Randomized Clinical Trial.

Type 2 diabetes mellitus (T2DM) is a serious public health problem accompanies with several complications. This study was conducted to evaluate the effects of chromium picolinate (CrPic) supplementation on the glycemic status and lipid profile in patients with T2DM. The patients with T2DM (n = 52) were randomly allocated into 2 groups. One group received 400 µg CrPic per day and the other group took placebo; the intervention duration was 8 weeks. Anthropometric indices and metabolic factors were measured at the beginning, and at end of the study. The patients were recommended not to change their normal diet, life style and medication. No significant changes were observed for weight, body mass index, and fasting blood glucose (FBG) in both groups; while intra-groups changes in homeostatic model assessment for insulin resistance (HOMA-IR) value was significant (p < 0.05). Results of analysis of covariance showed that there were significance differences between groups in total cholesterol, low density lipoprotein cholesterol and HOMA-IR at the end of the intervention adjusting for baseline levels (p = 0.035, 0.030 and < 0.001, respectively). In this study, oral supplementation with 400 µg CrPic for eight weeks did not alter FBG concentration as well as anthropometric parameters in individuals with T2DM. However, the modest beneficial effects of chromium supplementation on insulin resistance as indicated by HOMA-IR and lipid profile were found.

Effects of coenzyme Q10 supplementation on matrix metalloproteinases and DAS-28 in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled clinical trial.

OBJECTIVES: This study aimed to assess the effect of CoQ10 supplementation on serum matrix metalloproteinases (MMPs) and clinical parameters in rheumatoid arthritis (RA) patients. METHOD: In this randomized, double-blind, placebo-controlled trial, 54 RA patients who fulfilled the eligibility criteria (18-56 years, diagnosed at least 6 months ago, with DAS-28 > 3.2) were randomly assigned into two groups to receive 100 mg/day CoQ10 (n = 27) or placebo (n = 27) for 2 months. Serum MMP-1 and MMP-3 levels and clinical status using disease activity score in 28 joints (DAS-28) were assessed before and after supplementation. Data were analyzed using χ2, independent sample t test, paired t test, Wilcoxon, Mann-Whitney, and analysis of covariance. RESULTS: A significant reduction was observed in both CoQ10 and placebo groups in the medians of serum MMP-1 (0.2 to 0.16, P < 0.001), (0.18 to 0.15, P = 0.001); swollen joint count (2 to 0, P < 0.001), (2 to 0, P = 0.009); and the means of DAS-28 (5.01 ± 1.21 to 2.34 ± 0.68, P < 0.001), (4.88 ± 0.96 to 4.04 ± 1.36, P = 0.009) respectively. Serum MMP-3 level increased significantly in placebo group (2.26 to 2.57, P = 0.020), and the MMP-3 changes between groups were significant (P = 0.027). Furthermore, significant reductions were only observed in ESR, pain score, and tender joint count in CoQ10 group compared with baseline (P = 0.001, P < 0.001, and P < 0.001, respectively). Significant differences were observed between two groups in DAS-28, pain score, and swollen and tender joint count after the intervention (P < 0.001, P < 0.001, and P = 0.012 and P < 0.001, respectively). CONCLUSIONS: It seems that CoQ10 may provide a new complementary approach for RA patients.Key Points• CoQ10 supplementation in RA patients attenuated serum MMP-3 level.• CoQ10 supplementation in RA patients improved clinical outcomes and ameliorated disease severity.• CoQ10 may provide a new complementary approach for patients with RA.

Effects of Coenzyme Q10 Supplementation on Inflammatory Cytokines (TNF-α, IL-6) and Oxidative Stress in Rheumatoid Arthritis Patients: A Randomized Controlled Trial.

BACKGROUNDS AND AIMS: Overproduction of proinflammatory cytokines is a main trait of rheumatoid arthritis. Coenzyme Q10 (CoQ10), an endogenous antioxidant, has shown anti-inflammatory effects in some diseases. In this study we aimed to assess the effects of CoQ10 supplementation on cytokines generation and oxidative stress in rheumatoid arthritis. METHODS: In this double-blind, randomized controlled clinical trial, 44 patients with rheumatoid arthritis were recruited. Twenty two patients received 100 mg/day capsules of CoQ10 and 22 patients took placebo for 2 months. At the beginning and the end of the intervention, 7 mL of fasting blood was taken from patients to measure malondialdehyde (MDA), total antioxidant capacity (TAC), interleukin (IL)-6 and tumor necrosis factor alpha (TNF-α). RESULTS: At the end of the study, serum MDA significantly decreased in supplemented group (mean difference = -1.47 nmol/mL; 95% confidence interval (CI), -2.52 to -0.43; p = 0.008). CoQ10 also suppressed overexpression of TNF-α (difference in median was +1.1 in placebo vs. +0.03 in CoQ10 group; p = 0.033). There was no significant difference in TAC and IL-6 levels between groups. CONCLUSIONS: This study showed beneficial effects of CoQ10 supplementation on inflammatory cytokines and oxidative stress in rheumatoid arthritis patients.

Effect of vitamin C supplementation on oxidative stress and lipid profiles in hemodialysis patients.

BACKGROUND AND AIMS: The increase in oxidative stress is the main factor in acceleration of atherosclerosis, leading to death in hemodialysis patients. Vitamin C is one of the most important antioxidants that inhibits lipid peroxidation and improves endothelial function. This study aims to assess the effects of vitamin C supplementation on lipid profiles as well as markers of lipid peroxidation among hemodialysis patients. MATERIALS AND METHODS: In this double-blind, randomized, controlled clinical trial, a total of 42 patients were randomly assigned to vitamin C (n=21) or placebo groups (n=21). Patients in the vitamin C group consumed 250 mg vitamin C and those in the placebo group were given placebo every other day for 12 weeks. Fasting blood samples were collected at baseline and at the end of the study to measure serum concentrations of lipid profiles, as well as malondialdehyde (MDA) and vitamin C. RESULTS: After supplementation with vitamin C, serum vitamin C levels increased significantly in the vitamin C group as compared to baseline (p=0.033). There was also a significant difference in serum vitamin C levels between vitamin C and placebo groups (p=0.001). Serum MDA concentrations were marginally decreased in the vitamin C group after taking supplements (p=0.057). A significant difference was also seen in mean MDA changes between vitamin C and placebo groups (p=0.002). There was a significant difference in serum levels of total cholesterol (p=0.005), low-density lipoprotein (LDL-C) (p=0.012), and LDL-C/high-density lipoprotein (HDL-C) ratio (p=0.018) between the two groups; however, serum triglyceride and HDL-C levels were not significantly different between groups. CONCLUSION: Every other day supplementation with 250 mg vitamin C for 12 weeks increases serum vitamin C, decreases MDA levels, and improves lipid profiles in hemodialysis patients.